pubmed-article:12860493 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:12860493 | lifeskim:mentions | umls-concept:C0003873 | lld:lifeskim |
pubmed-article:12860493 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
pubmed-article:12860493 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
pubmed-article:12860493 | lifeskim:mentions | umls-concept:C0031809 | lld:lifeskim |
pubmed-article:12860493 | lifeskim:mentions | umls-concept:C0027540 | lld:lifeskim |
pubmed-article:12860493 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
pubmed-article:12860493 | lifeskim:mentions | umls-concept:C0025677 | lld:lifeskim |
pubmed-article:12860493 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
pubmed-article:12860493 | lifeskim:mentions | umls-concept:C1122087 | lld:lifeskim |
pubmed-article:12860493 | lifeskim:mentions | umls-concept:C0031928 | lld:lifeskim |
pubmed-article:12860493 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
pubmed-article:12860493 | lifeskim:mentions | umls-concept:C0521115 | lld:lifeskim |
pubmed-article:12860493 | pubmed:issue | 6 | lld:pubmed |
pubmed-article:12860493 | pubmed:dateCreated | 2003-7-15 | lld:pubmed |
pubmed-article:12860493 | pubmed:abstractText | Because traditional therapies for rheumatoid arthritis (RA) such as methotrexate (MTX) do not produce an adequate response in many patients, newer therapies that block the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) are increasingly being used in combination with MTX. | lld:pubmed |
pubmed-article:12860493 | pubmed:language | eng | lld:pubmed |
pubmed-article:12860493 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12860493 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:12860493 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12860493 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12860493 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12860493 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12860493 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12860493 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12860493 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:12860493 | pubmed:month | Jun | lld:pubmed |
pubmed-article:12860493 | pubmed:issn | 0149-2918 | lld:pubmed |
pubmed-article:12860493 | pubmed:author | pubmed-author:FurstDaniel... | lld:pubmed |
pubmed-article:12860493 | pubmed:author | pubmed-author:WeinblattMich... | lld:pubmed |
pubmed-article:12860493 | pubmed:author | pubmed-author:MorelandLarry... | lld:pubmed |
pubmed-article:12860493 | pubmed:author | pubmed-author:GrannemanG... | lld:pubmed |
pubmed-article:12860493 | pubmed:author | pubmed-author:KeystoneEdwar... | lld:pubmed |
pubmed-article:12860493 | pubmed:author | pubmed-author:WeismanMichae... | lld:pubmed |
pubmed-article:12860493 | pubmed:author | pubmed-author:PaulusHarold... | lld:pubmed |
pubmed-article:12860493 | pubmed:author | pubmed-author:FischkoffStev... | lld:pubmed |
pubmed-article:12860493 | pubmed:author | pubmed-author:ChartashEllio... | lld:pubmed |
pubmed-article:12860493 | pubmed:author | pubmed-author:TeohLeah SLS | lld:pubmed |
pubmed-article:12860493 | pubmed:author | pubmed-author:VelagapudiRaj... | lld:pubmed |
pubmed-article:12860493 | pubmed:author | pubmed-author:Noertersheuse... | lld:pubmed |
pubmed-article:12860493 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:12860493 | pubmed:volume | 25 | lld:pubmed |
pubmed-article:12860493 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:12860493 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:12860493 | pubmed:pagination | 1700-21 | lld:pubmed |
pubmed-article:12860493 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:meshHeading | pubmed-meshheading:12860493... | lld:pubmed |
pubmed-article:12860493 | pubmed:year | 2003 | lld:pubmed |
pubmed-article:12860493 | pubmed:articleTitle | Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. | lld:pubmed |
pubmed-article:12860493 | pubmed:affiliation | Cedars-Sinai Medical Center, Los Angeles, California 90048, USA. weisman@cshs.org | lld:pubmed |
pubmed-article:12860493 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:12860493 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:12860493 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
pubmed-article:12860493 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:12860493 | pubmed:publicationType | Multicenter Study | lld:pubmed |
pubmed-article:12860493 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12860493 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12860493 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12860493 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12860493 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12860493 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12860493 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12860493 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12860493 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12860493 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12860493 | lld:pubmed |